AU2023211165A1 - A biopharmaceutical prodrug platform based on protein conformational change - Google Patents

A biopharmaceutical prodrug platform based on protein conformational change Download PDF

Info

Publication number
AU2023211165A1
AU2023211165A1 AU2023211165A AU2023211165A AU2023211165A1 AU 2023211165 A1 AU2023211165 A1 AU 2023211165A1 AU 2023211165 A AU2023211165 A AU 2023211165A AU 2023211165 A AU2023211165 A AU 2023211165A AU 2023211165 A1 AU2023211165 A1 AU 2023211165A1
Authority
AU
Australia
Prior art keywords
proteinaceous
seq
protein
construct according
loop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023211165A
Other languages
English (en)
Inventor
Jan Johannes ENGHILD
Seandean Lykke HARWOOD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus Universitet
Original Assignee
Aarhus Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aarhus Universitet filed Critical Aarhus Universitet
Publication of AU2023211165A1 publication Critical patent/AU2023211165A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2023211165A 2022-01-31 2023-01-31 A biopharmaceutical prodrug platform based on protein conformational change Pending AU2023211165A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22154258 2022-01-31
EP22154258.2 2022-01-31
PCT/EP2023/052280 WO2023144412A1 (en) 2022-01-31 2023-01-31 A biopharmaceutical prodrug platform based on protein conformational change

Publications (1)

Publication Number Publication Date
AU2023211165A1 true AU2023211165A1 (en) 2024-07-25

Family

ID=80118874

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023211165A Pending AU2023211165A1 (en) 2022-01-31 2023-01-31 A biopharmaceutical prodrug platform based on protein conformational change

Country Status (7)

Country Link
US (1) US20240374745A1 (https=)
EP (1) EP4473007A1 (https=)
JP (1) JP2025505434A (https=)
CN (1) CN118613501A (https=)
AU (1) AU2023211165A1 (https=)
CA (1) CA3243392A1 (https=)
WO (1) WO2023144412A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024261212A1 (en) * 2023-06-22 2024-12-26 Aarhus Universitet Multi-specific proteinaceous prodrug constructs
WO2025128434A1 (en) * 2023-12-14 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of ven/aza resistant acute myeloid leukemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2324864A1 (en) * 1998-04-01 1999-10-07 Duke University Immune response modulator alpha-2 macroglobulin complex
SG175602A1 (en) * 2006-07-05 2011-11-28 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
JP6861152B2 (ja) * 2014-11-20 2021-04-21 サイトニックス コーポレイション 治療用変異体アルファ２−マクログロブリン組成物
EP3762406A2 (en) * 2018-03-09 2021-01-13 Askgene Pharma, Inc. Cytokine prodrugs
AU2019271148B9 (en) * 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222282A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain

Also Published As

Publication number Publication date
CN118613501A (zh) 2024-09-06
CA3243392A1 (en) 2023-08-03
US20240374745A1 (en) 2024-11-14
WO2023144412A1 (en) 2023-08-03
EP4473007A1 (en) 2024-12-11
JP2025505434A (ja) 2025-02-26

Similar Documents

Publication Publication Date Title
JP7293456B2 (ja) 誘導性結合タンパク質及びその使用方法
CN114401997B (zh) 细胞因子前药和双前药
JP7460609B2 (ja) 活性化可能なインターロイキン－２ポリペプチド及びその使用方法
CN112534052B (zh) 全新il-21前药及使用方法
US20240327527A1 (en) Activatable antibodies and methods of use thereof
KR102771251B1 (ko) 제약된 조건적으로 활성화된 결합 단백질
US20240374745A1 (en) Biopharmaceutical prodrug platform based on protein conformational change
CN114390938B (zh) 受约束的条件性活化的结合蛋白
CN104704001B (zh) Asgpr抗体及其用途
JP2016155803A (ja) ヒトインスリン受容体を介する医薬品の送達
CN114173876A (zh) 含有靶向肿瘤抗原的Fc区和部分的条件性活化的结合蛋白质
EP4208480A2 (en) Constrained conditionally activated binding protein constructs with human serum albumin domains
CN116419925A (zh) 受限的条件激活的结合蛋白
JP2023552865A (ja) 条件付き二重特異性結合タンパク質
KR20240111753A (ko) 개선된 항원 결합 수용체
US20230076768A1 (en) IL2 Orthologs and Methods of Use
AU2024312715A1 (en) Multi-specific proteinaceous prodrug constructs
HK40119423A (zh) 改善的folr1蛋白酶可活化的t细胞双特异性抗体
HK40001681A (en) Inducible binding proteins and methods of use